Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Non-Current Debt (2016 - 2025)

Ptc Therapeutics has reported Non-Current Debt over the past 12 years, most recently at $286.0 million for Q2 2025.

  • Quarterly results put Non-Current Debt at $286.0 million for Q2 2025, changed 0.42% from a year ago — trailing twelve months through Jun 2025 was $286.0 million (changed 0.42% YoY), and the annual figure for FY2024 was $285.4 million, changed 0.42%.
  • Non-Current Debt for Q2 2025 was $286.0 million at Ptc Therapeutics, roughly flat from $285.7 million in the prior quarter.
  • Over the last five years, Non-Current Debt for PTCT hit a ceiling of $573.2 million in Q3 2023 and a floor of $281.6 million in Q3 2021.
  • Median Non-Current Debt over the past 5 years was $285.3 million (2024), compared with a mean of $364.3 million.
  • Biggest five-year swings in Non-Current Debt: surged 102.81% in 2022 and later plummeted 50.29% in 2023.
  • Ptc Therapeutics' Non-Current Debt stood at $281.9 million in 2021, then soared by 102.81% to $571.7 million in 2022, then plummeted by 50.29% to $284.2 million in 2023, then increased by 0.42% to $285.4 million in 2024, then grew by 0.21% to $286.0 million in 2025.
  • The last three reported values for Non-Current Debt were $286.0 million (Q2 2025), $285.7 million (Q1 2025), and $285.4 million (Q4 2024) per Business Quant data.